β-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease

Brain

Volumn 130, Issue 11, 2007, Pages 2837-2844

  Pike, Kerryn E ^a   Savage, Greg ^a,g   Villemagne, Victor L ^b,c,d   Ng, Steven ^b   Moss, Simon A ^a   Maruff, Paul ^c,d,e   Mathis, Chester A ^f   Klunk, William E ^f   Masters, Colin L ^c,d   Rowe, Christopher C ^b,c  

^a MONASH UNIVERSITY   (Australia)

^b AUSTIN HEALTH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^e Cogstate Pty Ltd ^*  (Australia)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g MACQUARIE UNIVERSITY   (Australia)

Author keywords

Alzheimer's disease; Beta amyloid; Memory performance; Mild cognitive impairment; PET imaging

Indexed keywords

AMYLOID BETA PROTEIN; CARBON 11; PITTSBURGH COMPOUND B C 11; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; BRAIN SCINTISCANNING; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE MARKER; DISEASE SEVERITY; EPISODIC MEMORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MEMORY DISORDER; MENTAL PERFORMANCE; MULTIPLE LINEAR REGRESSION ANALYSIS; NEUROIMAGING; NEUROPSYCHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE ANALYSIS; SENILE PLAQUE; TASK PERFORMANCE;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; BENZOTHIAZOLES; BIOLOGICAL MARKERS; CARBON RADIOISOTOPES; CASE-CONTROL STUDIES; CEREBELLAR CORTEX; CHI-SQUARE DISTRIBUTION; COGNITION DISORDERS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY; MIDDLE AGED; MUTATION; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY;

EID: 35648932901     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awm238     Document Type: Article

References (57)

1. Aggarwal NT, Wilson RS, Beck TL, Bienias JL, Bennett DA. Mild cognitive impairment in different functional domains and incident Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005; 76: 1479-84.
2. Aiken LS, West SG. Multiple regression: testing and interpreting interactions. Newbury Park, CA: Sage Publications; 1991.
3. Amieva H, Jacqmin-Gadda H, Orgogozo J-M, Le Carret N, Helmer C, Letenneur L, et al. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain 2005; 128: 1093-101.
4. 11C-PIB positron emission tomography study. Ann Neurol 2006; 60: 145-7.
5. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986; 51: 1173-82.
6. Bartoo GT, Nochlin D, Chang D, Kim Y, Sumi SM. The mean Aβ load in the hippocampus correlates with duration and severity of dementia in subgroups of Alzheimer disease. J Neuropathol Exp Neurol 1997; 56: 531-40.
7. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006; 66: 1837-44.
8. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 2004; 61: 378-84.
9. Benton A. Differential behavioral effects of frontal lobe disease. Neuropsychologia 1968; 6: 53-60.
10. Beyreuther K, Dyrks T, Hilbich C, Monning U, Konig G, Multhaup G, et al. Amyloid precursor protein (APP) and beta A4 amyloid in Alzheimer's disease and Down syndrome. Prog Clin Biol Res 1992; 379: 159-82.
11. Blacker D, Tanzi, RE. The genetics of Alzheimer disease: current status and future prospects. Arch Neurol 1998; 55: 294-6.
12. Braak H, Braak E. Neuropathological staging of Alzheimer related changes. Acta Neuropathol (Berl) 1991; 82: 239-59.
13. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005; 25: 7709-17.
14. Busse A, Angermeyer MC, Riedel-Heller SG. Progression of mild cognitive impairment to dementia: a challenge to current thinking. Br J Psychiatry 2006a; 189: 399-404.
15. Busse A, Hensel A, Gühne U, Angermeyer MC, Riedel-Heller SG. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 2006b; 67: 2176-85.
16. Bussière T, Friend PD, Sadeghi N, Wicinski B, Lin GI, Bouras C, et al. Stereological assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer's disease. Neuroscience 2002; 112: 75-91.
17. Cohen NJ, Eichenbaum H. Memory, amnesia, and the hippocampal system. Cambridge: The MIT Press; 1993.
18. Cummings BJ, Pike CJ, Shankle R, Cotman CW. β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging 1996; 17: 921-33.
19. Delis DC, Kramer JH, Kaplan E, Ober BA. CVLT-II: California Verbal Learning Test Second Edition Adult Version. San Antonio, TX: The Psychological Corporation; 2000.
20. 18F] FDG PET study. Neurology 2007; 68: 501-8.
21. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129: 2856-66.
22. 42 in humans. Ann Neurol 2006; 59: 512-9.
23. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-7.
24. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
25. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2007 (in press), doi:10.1016/j.neurobiolaging.2007. 03.029. [epub ahead of print: May 10, 2007].
26. Giannakopoulos P, Herrmann FR, Bussière T, Bouras C, Kövari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003; 60: 1494-500.
27. Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol 2003; 60: 729-36.
28. Johnson SC, Schmitz TW, Moritz CH, Meyerand ME, Rowley HA, Alexander AL, et al. Activation of brain regions vulnerable to Alzheimer's disease: the effect of mild cognitive impairment. Neurobiol Aging 2006; 27: 1604-12.
29. Kanne SM, Balota DA, Storandt M, McKeel DW Jr, Morris JC. Relating anatomy to function in Alzheimer's disease: neuropsychological profiles predict regional neuropathology 5 years later. Neurology 1998; 50: 979-85.
30. 11C] PIB uptake in Alzheimer disease. Neurology 2006; 67: 1575-80.
31. Klein WL. Synaptic targeting by Aβ oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease. Alzheimers Dement 2006; 2: 43-55.
32. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004; 55: 306-19.
33. Klunk WE, Wang Y, Huang G-F, Debnath ML, Holt DP, Shao L, et al. The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003; 23: 2086-92.
34. Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR. Neuropathologic substrate of mild cognitive impairment. Arch Neurol 2006; 63: 38-46.
35. Masters CL, Beyreuther K. Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Aβ amyloid pathway. Brain 2006; 129: 2823-9.
36. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984; 34: 939-44.
37. Meyers JE, Meyers KR. Rey Complex Figure Test and Recognition Trial. Odessa: Psychological Assessment Resources Inc.; 1995.
38. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997; 42: 85-94.
39. Mintun MA, LaRossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-52.
40. Mufson EJ, Chen E-Y, Cochran EJ, Beckett LA, Bennett DA, Kordower JH. Entorhinal cortex β-amyloid load in individuals with mild cognitive impairment. Exp Neurol 1999; 158: 469-90.
41. Nagy Z, Jobst KA, Esiri MM, Morris JH, King EM-F, MacDonald B, et al. Hippocampal pathology reflects memory deficit and brain imaging measurements in Alzheimer's disease: clinicopathologic correlations using three sets of pathologic diagnostic criteria. Dementia 1996; 7: 76-81.
42. Nestor PJ, Scheltens P, Hodges JR. Advances in early detection of Alzheimer's disease. Nat Rev Neurosci 2004; 5: s34-41.
43. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-92.
44. Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006; 63: 665-72.
45. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005; 25: 1528-47.
46. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999; 45: 358-68.
47. Prohovnik I, Perl DP, Davis KL, Libow L, Lesser G, Haroutunian V. Dissociation of neuropathology from severity in late-onset Alzheimer disease. Neurology 2006; 66: 49-55.
48. 2+ homeostasis. Brain Res 2007; 1143: 11-21.
49. Roder S, Danober L, Pozza MF, Lingenhoehl K, Wiederhold K-H, Olpe HR. Electrophysiological studies on the hippocampus and prefrontal cortex assessing the effects of amyloidosis in amyloid precursor protein 23 transgenic mice. Neuroscience 2003; 120: 705-20.
50. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging β-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-25.
51. Saxton J, Ratcliff G, Munro CA, Coffey E, Becker JT, Fried L, et al. Normative data on the Boston Naming Test and two equivalent 30-item short forms. Clin Neuropsychol 2000; 14: 526-34.
52. Squire LR, Zola SM. Structure and function of declarative and nondeclarative memory systems. Proc Natl Acad Sci USA 1996; 93: 13515-22.
53. Thomas A, Ballard C, Kenny RA, O'Brien J, Oakley A, Kalaria R. Correlation of entorhinal amyloid with memory in Alzheimer's and vascular but not Lewy body dementia. Dement Geriatr Cogn Disord 2005; 19: 57-60.
54. Weaver Cargin J, Maruff P, Collie A, Masters C. Mild memory impairment in healthy older adults is distinct from normal aging. Brain Cogn 2006; 60: 146-55.
55. Wechsler D. WAIS-III administration and scoring manual. San Antonio, TX: Psychological Corporation; 1997.
56. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund L-O, et al. Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256: 240-6.
57. Zekanowski C, Religa D, Graff C, Filipek S, Kuznicki J. Genetic aspects of Alzheimer's disease. Acta Neurobiol Exp (Wars) 2004; 64: 19-31.